Scientific exchange is the non-promotional, balanced sharing of clinical and scientific information between a life-science company's Medical Affairs representatives — typically MSLs — and healthcare professionals, conducted independently of any sales or marketing objective. It is the core activity that distinguishes Medical Affairs' field function from a commercial one: information flows both ways, in the service of scientific accuracy rather than product promotion.
Scientific exchange is the legal and ethical foundation that allows MSLs to operate as trusted, non-commercial scientific resources rather than an extension of the sales force. Getting the boundary right protects the organization from regulatory risk and protects the credibility that makes MSL relationships valuable in the first place — a KOL who suspects a conversation was promotional stops trusting everything that MSL says afterward.
It's also, increasingly, a data source. Every compliant scientific exchange interaction is a potential insight — about an evidence gap, an emerging clinical question, an unmet need — that has value well beyond the conversation itself, provided it gets captured and routed rather than lost to memory.
The line is defined by direction and framing, not topic. On-label clinical discussion is always permitted. Off-label discussion is where the distinction matters most: under FDA's unsolicited request framework, an MSL may respond to a genuine, HCP-initiated question about an unapproved use with truthful, balanced, non-misleading information — but may never proactively raise the topic. The FDA's 2023 draft guidance on Scientific Information on Unapproved Uses (SIUU) reinforced this standard, requiring that firm communications about unapproved uses be scientifically sound, clearly disclosed as off-label, and kept structurally separate from promotional content and channels.
A practical distinction some compliance teams use: promotional content is designed to persuade; scientific exchange content is designed to inform, and is tailored only to answer the specific question actually asked.
Because the line between exchange and promotion is a matter of judgment applied in real time, documentation is what makes the distinction defensible after the fact. Best practice is to log every off-label or unsolicited-request interaction — what was asked, what was said, and what source material supported the response — as part of a formal compliance record, with routing to a medical review or Medical Information function for anything outside routine on-label discussion.
TikaMobile treats scientific exchange as both a compliance-sensitive activity and a genuine insight source, capturing it with the structure both purposes require.
Explore TikaMobile's KOL Engagement platform →
Related: Medical Science Liaison (MSL) · Key Opinion Leader (KOL) · Medical Communications · Advisory Board (Pharma)